ArticleMolecular vision2010
Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease.
Article in Molecular vision, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04198740 (Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface), which is not on this map. Cited by 188 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface
Who cites it
188 citing papers in PubMed, 2 syntheses or guidelines pooled it, 308 citations in OpenAlex.
- Efficacy of intense pulsed light therapy on signs and symptoms of dry eye disease: A meta-analysis and systematic review.Indian journal of ophthalmology · 2023Pooled it
- Tear Biomarkers in Alzheimer's and Parkinson's Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review).International journal of molecular sciences · 2022Pooled it
- Randomized, double-masked, sham-controlled trial of efficacy and safety of quantum molecular resonance for treating meibomian gland dysfunction.Eye (London, England) · 2025Trial
- Efficacy of bandage contact lens for the management of dry eye disease after cataract surgery.International ophthalmology · 2021Trial
- Efficacy of topical bevacizumab 0.05% eye drops in dry eye disease: A double-masked, randomized trial.PloS one · 2020Trial
- Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eye.Drug design, development and therapy · 2015Trial
- Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures.Investigative ophthalmology & visual science · 2013Trial
- Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral supplementation with antioxidants and essential fatty acids.Clinical interventions in aging · 2013Trial
- A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction.Clinical interventions in aging · 2013Trial
- Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders.Clinical interventions in aging · 2013Trial
- Eyes of Fibromyalgia.Biomedicines · 2026Article
- Lyophilized Amniotic Membrane Eye Drops Stabilize the Tear Film in Dry Eye Disease: A Prospective Cohort Study.Journal of clinical medicine · 2026Article
- Oxidative Stress in Dry Eye Disease: Molecular Mechanisms and Emerging Therapeutic Strategies.Biomolecules · 2026Review
- Inflammatory molecules in tear fluid in retinitis pigmentosa: an exploratory case-control study.Scientific reports · 2026Observational
- Pharmacological, Natural and Emerging Therapies for Meibomian Gland Dysfunction: A Review.Drugs · 2026Review
- Topical Application of Preserved and Unpreserved Bevacizumab Eye Drops Improves Ocular Surface Parameters in Dogs with Chronic Keratitis: A Pilot Study.Veterinary sciences · 2026Article
- A comprehensive review of tear fluid proteome alterations in dry eye disease: Insights into pathophysiology and biomarker potential.The ocular surface · 2026Review
- Recent advances in smart contact lenses.Biosensors & bioelectronics: X · 2026Article
- The effect of diquafosol on tear film inflammatory markers in patients with dry eye: A noncomparative, open-label, proof-of-concept study.The Journal of international medical research · 2025Article
- Long-Term Clinical and Molecular Changes in Dry Eye Disease and Chronic Ocular Pain.International journal of molecular sciences · 2025Article
128 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeInflammatory molecules have been demonstrated in the tear film of patients with severe dry eye disease (DED). However, little attention has been paid to the most frequent moderate forms of DED. This study analyzes tear cytokine levels and their clinical correlations in patients with moderate evaporative-type DED due to meibomian gland disease (MGD).
methodsTwenty three evaporative-type DED patients (46 eyes) of mild-to-moderate intensity and nine healthy subjects (18 eyes) were recruited. Two symptom questionnaires were self-answered and multiple DED-related clinical tests were performed. Unstimulated tears from each eye were isolated and were not pooled. Levels of 15 cytokines and chemokines were measured by multiplex bead analysis, compared with control levels, and correlated with clinical tests.
resultsFourteen out of the 15 molecules were reliably detected in 1 microl of unstimulated tears from DED patients. Epidermal growth factor (EGF), fractalkine/CX3CL1, interleukin (IL) 1-receptor antagonist (Ra), IL-8/CXCL8, interferon inducible protein (IP)-10/CXCL10, and vascular endothelial growth factor (VEGF) were found in 94%-100% of samples; IL-6 in 65% (significantly more detected in older patients); IL-1beta, interferon gamma (IFN-gamma), and IL-10 in 30%-48%; IL-17 in 13%; granulocyte macrophage colony stimulating factor (GM-CSF), IL-13, and tumor necrosis factor alpha (TNF-alpha) in 2%-9%; and IL-5 was never detected. EGF, fractalkine/CX3CL1, IL-1Ra, IP-10/CXCL10, and VEGF levels were significantly increased compared to normal controls. Pain was correlated with IL-6 and IL-8/CXCL8. Tear break-up time correlated inversely with IL1-Ra. Schirmer test and tear lysozyme levels negatively correlated with IL-1Ra, IL-8/CXCL8, fracktalkine/CX3CL1, IL-6, IP-10/CXCL10, and VEGF had the same tendency. Conjunctival staining correlated negatively with EGF and positively with IL-6.
conclusionsIn this sample of moderate evaporative-type DED patients, five inflammatory molecules were elevated. Fracktalkine was demonstrated to be present and elevated in tears in human DED. IL-1Ra, IL-6, IL-8/CXCL8, and EGF levels correlated with pain and with clinical parameters measuring tear stability, tear production or ocular surface integrity. These results suggest that inflammation plays a role not only in severe DED but also in moderate evaporative DED.
Indexed as
Identifiers
20508732PMC2874579W1542814291What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.